Clinical Trials
Home > Cancer (Oncology) > Research and Clinical Trials > Clinical Trials
Print

Research and Clinical Trials

Clinical Trials

Search Cancer Clinical TrialsAs the University Hospital for Albert Einstein College of Medicine, Montefiore Medical Center believes in using the power of research to improve technologies, therapies and outcomes for our patients so that they may live longer, healthier lives.

Unique Treatment and Drug Therapy Options for Patients

We believe cancer treatments should be as unique as each of our patients. We are developing as many highly effective therapies as possible to offer patients ample options in order to determine the right drug or combination of drugs for their individual situation.

Our patients are given opportunities to participate in early-stage studies to determine if a new therapy effectively works for them. The trials are preceded by intensive and extensive laboratory research, and the potential benefits of participating in these clinical studies are numerous, including the opportunity for our patients to receive the latest treatments long before they are available anywhere else.

Trying an experimental therapy can be both exciting and a little frightening. Our focus is on the needs and concerns of participants, and we offer every assurance that each of our patients is completely in control of the process. We are vigilant about qualifying and approving candidates for specific studies. Additionally, each patient participates voluntarily and can choose to stop treatment at any time.

We have close to 200 active clinical trials and are currently recruiting for a number of studies.


Seeking Patients with Colon or Rectal Cancer that has Spread to the Liver (Research Study)
Randomized, Double-Blind, Phase II Trial of Radiofrequency Ablation + Lyso -Thermosensitive Liposomal Doxorubicin (ThermoDox®) for Colorectal Liver Metastases ≥ 2 cm Maximum Diameter

Seeking patients, 18 years and older, with a recent diagnosis of colorectal cancer spread to the liver. Cancer cannot have spread to other organs of the body. Patients must be found to be suitable for surgical/imaging procedure which will use chemotherapy and radio waves to treat liver masses caused by colorectal cancer.

For more information please contact Estella Forbes at 718-862-8840.


Seeking Patients with Untreated Cancer of Colon/Rectum, Appendix, Stomach, or Their Coatings that has Spread to the Inner Abdominal Cavity's Layer (Surgical Research Study)
Phase II Trial of Cytoreduction + Hyperthermic Intraperitoneal Mitomycinc+ Standard Systemic Therapy in Patients with Peritoneal Carcinomatosis

Seeking patients, 18 years and older, with a newly found and not yet treated colon, rectal, or other abdominal cancer that has been found to have spread to the lining of the abdominal cavity. Cancer cannot involve the liver or pancreas and patient should have adequate liver and kidney functioning. Patients must be found suitable to undergo surgery for their abdominal cancer.

For more information please contact Estella Forbes at 718-862-8840.


Seeking Patients with Colon Cancer that has Spread to the Tissues Lining the Abdominal Cavity (Research Study)
Pilot /Phase III Randomized Trial Comparing Best Available Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin-C + Best Available Systemic Therapy in Patient with Limited Peritoneal Dissemination of Colon Adenocarcinoma

Seeking patients, 18 years and older, with a newly found and not yet treated colon cancer that has spread to the lining of the abdominal cavity. Cancer should not involve the liver and patient should have adequate liver and kidney functioning. Patients must be found suitable to undergo surgery for their abdominal cancer.

For more information please contact Estella Forbes at 718-862-8840.


Seeking Patients with Carcinoid Tumors that Have Spread to Other Parts of Their Body (Research Study)
A Multicenter, Randomized, blinded efficacy and safety study of pasireotide LAR vs. octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues

Seeking patients, 18 years and older, that have a carcinoid tumor that has spread to other areas than where it was first found. Patients must have symptoms, diarrhea (more than four times per day) and flushing (more than 14 times per day), which are not well controlled by other medications. Patients should have good organ functioning and no major heart condition. Patients will receive a monthly injection for six to 18 months of a medication to assist in controlling their symptoms.

For more information please contact Estella Forbes at 718-862-8840.


Seeking Patients with Recurrent Prostate Cancer Following External Beam Radiation Therapy (Research Study)
A multicenter clinical study of the Sonablate ® 500 for the treatment of locally recurrent prostate cancer with HIFU (STAR Trial)

Seeking patients with recurrent prostate cancer following external beam radiation therapy (this is prostate cancer that has come back after being treated with external beam radiation therapy ("x-ray treatments).

The Sonablate® device is an experimental device used for the treatment of prostate cancer. This procedure, commonly known as HIFU uses an ultrasound transducer (a device that sends out sound waves) to focus high intensity ultrasound (sound wave energy) on the prostate tissue, which acts to destroy prostate tissue and the cancer cells. HIFU therapy has previously been used in humans for primary treatment of prostate cancer and following external beam radiation ("x-ray treatment") therapy for the treatment of prostate cancer.

If you agree to participate, you will be one of approximately 202 subjects in 20 centers participating in this study.

For more information please contact Hilda Haynes-Lewis at 718-920-8819.


Seeking Patients with Newly Diagnosed Low-Risk or Immediate-Risk Adenocarcinoma of the Prostate (Research Study)
A phase I dose escalation study using ultra-hypo fractionated, image-guided, intensity- modulated radiation therapy in prostate cancer.

Seeking patients with newly diagnosed low- risk or intermediate-risk adenocarcinoma of the prostate. The patient must be 18 years or older without significant kidney, bladder or liver dysfunction, no evidence of metastatic disease or chronic prostatitis. Patients will receive external beam radiation therapy on a hypofractionated schedule of five fractions instead of conventional radiation therapy of 40-42 treatments.

For more information please contact Hilda Haynes-Lewis at 718-920-8819.